Overview

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

Eligibility

Key Inclusion Criteria:

1. a. BMI \> 30 kg/m2 and BMI \< 42 kg/m2, OR b. BMI ≥ 27 kg/m2 and BMI \<30 kg/m2 with at least one weight-related co-morbidity
2. History of at least one self-reported unsuccessful dietary effort to lose body weight.
3. Stable body weight and stable physical activity within 3 months prior to screening per participant self-report.
4. All participants must adhere to protocol contraception requirements

Key Exclusion Criteria:

1. History of diabetes, including individuals with a HbA1c of ≥ 6.5% at Screening
2. Non-ambulatory participants, defined as unable to take at least 10 steps independently.
3. Females currently pregnant or breastfeeding, or who intend to become pregnant or to breastfeed.
4. Participation in another investigational clinical trial while participating in this clinical trial